公开(公告)号：US4941920A

公开(公告)日：1990-07-17

申请号：US274561

申请日：1988-11-23

申请人： Tsutomu Inui ,  Shun-ichiro Matsumoto ,  Rokuo Ichiyasu ,  Takeo Mizuguchi

发明人： Tsutomu Inui ,  Shun-ichiro Matsumoto ,  Rokuo Ichiyasu ,  Takeo Mizuguchi

IPC分类号： C22C1/04 ,  C22C19/07 ,  C23C14/34 ,  G11B5/851 ,  H01F41/18

CPC分类号： C22C1/0433 ,  C23C14/3414 ,  G11B5/851 ,  H01F41/18

摘要： A sintered target member consisting essentially of 50-75 weight % of Co, 3-12 weight % of Cr and balance substantially Ni, which has a structure comprising dispersion phases consisting essentially of one or more elements constituting the target member and having a maximum permeability of 50 or less. This target member is produced by mixing metal or alloy powders corresponding to low-permeability dispersion phases, charging the resulting mixture into a metal container; sealing the metal container under reduced pressure; sintering it at a temperature of 900.degree.-1300.degree. C. and pressure of 500 atm or more; and removing the metal container from the resulting sintered body.

摘要翻译： 基本上由Co组成的重量百分比为50-75％，Cr为3-12％（重量），余量基本上为Ni的烧结靶材，其结构包括基本上由一种或多种元素构成的构件， 为50以下。 该目标构件通过混合对应于低渗透分散相的金属或合金粉末而制成，将所得混合物装入金属容器中; 在减压下密封金属容器; 在900〜1300℃的温度和500atm以上的压力下烧结; 并从所得烧结体中移除金属容器。

公开(公告)号：US20090119786A1

公开(公告)日：2009-05-07

申请号：US11919709

申请日：2006-10-11

申请人： Mitsuyuki Matsumoto ,  Shun-ichiro Matsumoto

发明人： Mitsuyuki Matsumoto ,  Shun-ichiro Matsumoto

IPC分类号： G01N33/483 ,  A01K67/027 ,  A61K35/12

CPC分类号： A01K67/0275 ,  A01K2217/052 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0356 ,  C07K14/70571 ,  C07K14/723 ,  C12N15/8509 ,  C12N2830/008 ,  C12N2830/85

摘要： A non-human transgenic animal exhibiting schizophrenic symptoms in which a polynucleotide encoding SREB2 whose overexpression in the brain causes schizophrenia and a polynucleotide comprising a promoter are introduced; and a method of screening for a therapeutic agent for schizophrenia, comprising the steps of administrating a test substance to the animal, determining a schizophrenia-related disorder in the animal, and selecting the substance exhibiting a therapeutic effect on schizophrenia are disclosed. According to the present invention, a model animal of schizophrenia in which the genetic background that causes schizophrenia is reflected, and an in vivo screening method for a therapeutic agent for schizophrenia can be provided.

摘要翻译： 表现出精神分裂症状的非人转基因动物，其中引入了编码在脑中过表达的精神分裂症的SREB2的多核苷酸和包含启动子的多核苷酸的精神分裂症状症状; 以及筛选精神分裂症治疗剂的方法，包括以下步骤：向动物施用测试物质，测定动物中的精神分裂症相关病症，并选择对精神分裂症具有治疗作用的物质。 根据本发明，可以提供反映精神分裂症的遗传背景的精神分裂症的模型动物，并且可以提供用于精神分裂症的治疗剂的体内筛选方法。